[HTML][HTML] Celecoxib-erlotinib combination delays growth and inhibits angiogenesis in EGFR-mutated lung cancer
YX Li, J Le Wang, M Gao, H Tang, R Gui… - American Journal of …, 2016 - ncbi.nlm.nih.gov
Combination treatment for non-small cell lung cancer (NSCLC) is becoming more popular
due to the anticipation that it may be more effective than single drug treatment. In addition …
due to the anticipation that it may be more effective than single drug treatment. In addition …
Dual blockade of epidermal growth factor receptor (EGFR) and cyclooxygenase 2 (COX 2) may be dependent upon the EGFR mutational status in non-small cell lung …
SM Gadgeel, S Ali, P Philip, A Wozniak… - Journal of Clinical …, 2006 - ascopubs.org
7170 Background: Recent data has shown that the benefit of EGFR TKIs (tyrosine kinase
inhibitors) in NSCLC is in patients with tumors that have EGFR mutations and/or gene …
inhibitors) in NSCLC is in patients with tumors that have EGFR mutations and/or gene …
[HTML][HTML] Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo
JG Lee, R Wu - Neoplasia, 2015 - Elsevier
Combination treatment for non–small cell lung cancer (NSCLC) is becoming more popular
due to the anticipation that it may be more effective than single drug treatment. In addition …
due to the anticipation that it may be more effective than single drug treatment. In addition …
Retracted: Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase‐2 in nonsmall cell lung cancer may be dependent on the EGFR …
SM Gadgeel, S Ali, PA Philip, F Ahmed… - … Journal of the …, 2007 - Wiley Online Library
BACKGROUND. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs)
have demonstrated clinical benefit in patients with nonsmall cell lung cancer (NSCLC) …
have demonstrated clinical benefit in patients with nonsmall cell lung cancer (NSCLC) …
A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non–small cell lung cancer
KL Reckamp, K Krysan, JD Morrow, GL Milne… - Clinical cancer …, 2006 - AACR
Abstract Purpose: Overexpression of cyclooxygenase-2 (COX-2) activates extracellular
signal-regulated kinase/mitogen-activated protein kinase signaling in an epidermal growth …
signal-regulated kinase/mitogen-activated protein kinase signaling in an epidermal growth …
Randomized phase 2 trial of erlotinib in combination with high‐dose celecoxib or placebo in patients with advanced non‐small cell lung cancer
KL Reckamp, M Koczywas, MC Cristea, JE Dowell… - Cancer, 2015 - Wiley Online Library
BACKGROUND Cyclooxygenase 2 (COX‐2)‐dependent signaling represents a potential
mechanism of resistance to therapy with epidermal growth factor receptor (EGFR) tyrosine …
mechanism of resistance to therapy with epidermal growth factor receptor (EGFR) tyrosine …
Efficacy of erlotinib and celecoxib for patients with advanced non-small cell lung cancer: A retrospective study
YH Jin, WH Li, Y Bai, L Ni - Medicine, 2019 - journals.lww.com
Efficacy of erlotinib and celecoxib for patients with advanc... : Medicine Efficacy of erlotinib and
celecoxib for patients with advanced non-small cell lung cancer: A retrospective study : Medicine …
celecoxib for patients with advanced non-small cell lung cancer: A retrospective study : Medicine …
[HTML][HTML] Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring EGFR mutations …
K Yoshida, Y Yamada - Translational Lung Cancer Research, 2015 - ncbi.nlm.nih.gov
© Translational lung cancer research. All rights reserved. Transl Lung Cancer Res 2015; 4
(3): 217-219 www. tlcr. org patients with advanced NSCLC harboring EGFR-activating has …
(3): 217-219 www. tlcr. org patients with advanced NSCLC harboring EGFR-activating has …
Decline in serum soluble E-cadherin and low baseline matrix metalloproteinase-9 are associated with response to combination celecoxib and erlotinib therapy in …
KL Reckamp, BK Gardner, RA Figlin… - Journal of Clinical …, 2007 - ascopubs.org
7640 Background: Cyclooxygenase-2 (COX-2) overexpression may mediate resistance to
EGFR TK inhibition through prostaglandin E2 (PGE2)-dependent promotion of epithelial to …
EGFR TK inhibition through prostaglandin E2 (PGE2)-dependent promotion of epithelial to …
Gefitinib and celecoxib in patients with platinum refractory non-small cell lung cancer (NSCLC)
SM Gadgeel, NJ Shehadeh, JC Ruckdeschel… - Journal of Clinical …, 2004 - ascopubs.org
7094 Background: Chemotherapy response rates in platinum refractory NSCLC are very
limited. Geftinib (Iressa), an Epidermal Growth Factor Receptor (EGFR) inhibitor …
limited. Geftinib (Iressa), an Epidermal Growth Factor Receptor (EGFR) inhibitor …